We're adding to our position in a stock that has gotten cheaper since earnings

Jim Cramer's Charitable Trust is buying 50 shares of Cardinal Health at roughly $199, lifting its position to 525 shares and portfolio weight to 2.75% from 2.50%. The purchase follows last week's post-earnings decline, even after Cardinal reported a revenue miss and $184 million of impairment charges, because analysts raised fiscal 2027 EPS estimates to $11.91 from about $11.60 and the stock now trades at about 16.5x forward earnings versus roughly 20x in early March. The article frames the pullback as a valuation opportunity rather than a fundamental deterioration.

Analysis

The important signal here is not the headline buy, but the market’s willingness to reward a quality compounder even after a messy quarter. For a distributor with relatively predictable cash generation, a lower multiple plus rising forward estimates is the ideal setup: the equity can re-rate without needing a perfect fundamental print. That makes CAH more of a duration-style defensive compounder than a pure earnings momentum name, which is why the post-earnings drawdown may have created a better entry than the prior low-teens gap-up phase.

The second-order issue is that impairment charges around adjacent growth initiatives can actually be constructive if they clear the deck for more disciplined capital allocation. If management can keep EPS growth in the low-to-mid teens while investors stop underwriting questionable adjacencies, the stock deserves a steadier multiple floor. The real risk is that the market extrapolates this quarter’s non-operating noise into a broader skepticism about acquisition or platform returns, which would cap multiple expansion even if EPS continues to rise.

Near term, the catalyst path is mostly estimate revision rather than revenue acceleration. If consensus keeps drifting up over the next 1-2 quarters, CAH can grind higher simply via denominator relief and modest multiple expansion, especially given how quickly the stock de-rated. The contrarian point is that the move may already reflect the easy re-rating; from here, upside likely requires either another round of estimate increases or a clean narrative reset on the impaired assets, otherwise the stock can become a slow mover despite solid fundamentals.

Key Decisions for Investors

• Stay long CAH for a 3-6 month horizon; add on weakness toward the high-teens P/E equivalent if forward EPS remains intact. Risk/reward favors a 10-15% rerating if estimates keep moving up, with limited downside unless guidance deteriorates.
• Pair long CAH vs. short a lower-quality healthcare distributor or services name with more execution risk over the next 1-2 quarters. The trade isolates multiple expansion from balance-sheet/earnings quality and should work if the market continues to reward defensiveness.
• Use near-dated call spreads in CAH for a 1-3 month event-driven trade if you expect another analyst estimate reset higher. Target modest upside because implied volatility should stay contained, but upside is likely limited without a new catalyst.
• Do not chase if CAH gaps higher on sympathy buying; wait for post-rally consolidation. The best entry is after the market digests whether the impairment is a one-off or a sign of persistent capital misallocation.
• Set a risk trigger on any sign that 2027 EPS estimates stop rising over the next earnings cycle. If revisions flatten, trim exposure because the stock’s current valuation assumes continued low-teens EPS compounding.